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Summary 
Human epidermal Langerhans cells (LC) bearing IgE are found in disease states associated with 
hyperimmunoglobulinemia  E. When studying the mechanism(s) underlying this phenomenon, 
immunohistology  revealed that a majority of epidermal LC from normal skin of healthy individ- 
uals can specifically bind monomeric IgE. IgE binding to LC could neither be prevented by prein- 
cubation of the  tissue with  monoclonal antibodies  (mAb)  against  either FceRII/CD23  or 
Fc3,RII/CD32, nor by the addition of lactose. However, binding could be entirely abrogated 
by preincubation with the anti-FceRIo~ mAb 15-1, which interferes with IgE binding to FceR.Ic~/ 
transfectants. These observations indicated that IgE binding to epidermal LC is mediated by FceRI 
rather than by CD23, CD32, or the D-galactose-specific IgE-binding protein. This assumption 
gained support from our additional findings that: (a) the majority of LC exhibited distinct sur- 
face immunolabeling  with the anti-FceRIo~ mAbs 15-1 and 19-1, but not with any of eight different 
anti-FceRII/CD23 mAbs; and (b) transcripts for the c~, ~, and 3/chains of FceRI could be amplified 
by polymerase chain reaction from RNA preparations of LC-enriched, but not of LC-depleted, 
epidermal cell suspensions.  In view of the preeminent role of FceRI crosslinking on mast cells 
and basophils in triggering the synthesis and release of mediators of allergic reactions, the demon- 
stration of this receptor on epidermal LC may have important implications for our understanding 
of allergic reactions after  epicutaneous contact with allergens. 
S 
everal years ago, Bruynzeel-Koomen et al. (1) detected IgE- 
bearing Langerhans cells (LC) 1 in the skin of atopic der- 
matitis (AD) patients. This finding was confirmed by other 
investigators (2, 3) and was considered to be specific for AD. 
In 1988, Bruynzeel-Koomen et al. (4) showed that LC-enriched 
epidermal cells from AD patients can form rosettes with IgE- 
coated SRBC and that this phenomenon could be prevented 
by preincubation of the epidermal cells with either myeloma 
IgE or the mAb BB10 directed against the Fc-IgE receptor 
of eosinophils, platelets, and macrophages. Together with the 
observation that stimulation of LC-enriched epidermal cells 
from nonatopics with IL-4 and/or IFN-3,  results in anti- 
FceRII/CD23 reactivity of LC (5),  this finding led to the 
idea that LC from AD patients bind IgE via FceRII/CD23 
1 Abbreviations used in thist,  aper: AD, atopic dermatitis; EA, egg albumin; 
eBP, IgE-binding protein; LC, Langerhans cell; PLP, paraformaldehyde- 
lysine-periodate; WM, washing medium. 
induced by  cytokines uniquely  released  in  the  AD  skin 
microenvironment. Evidence contradicting this concept came 
from the recent finding that IgE + LC are also found in other 
disease states associated with hyperimmunoglobulinemia E 
(6).  Based on this observation, we reasoned that the IgE- 
binding capacity of LC may not be limited to those of dis- 
eased skin, but rather be an intrinsic property of these cells. 
Thus, this study was undertaken to test whether epidermal 
IC from normal skin of nonatopic persons could bind IgE 
and, if so, to unravel the nature of the IgE-binding structure. 
Materials and Methods 
Specimen  Collection 
Full- or split-thickness skin biopsies from clinically normal- 
appearing areas of 12 nonatopics were obtained during elective  sur- 
gery and from autopsy  specimens  using a dermatome  (Davol/Simon, 
Cranston, RI). 
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Frozen Sections.  For light microscopic immunolabeling studies, 
5-#m cryostat sections of snap-frozen (liquid nitrogen) full-thickness 
skin biopsies were prepared and acetone fixed for 10 rain at 4~ 
For ultrastructural investigations,  skin biopsy specimens were 
cut into small cubes and immediately fixed in paraformaldehyde- 
lysine-periodate (PLP) for 5 h at room temperature (7). The tissue 
was then transferred  to PBS/10% DMSO for 1 h at 20~  snap 
frozen, and stored  in liquid nitrogen. 
Epidermal Sheets.  Epidermal  sheets were obtained from kera- 
tomed split-thickness skin by a separation technique using dispase 
(2.5  U/ml;  Boehringer-Mannheim  Biochemicals,  Mannheim, 
FRG) (8). 
Epidermal CeUSuspensions.  Keratomed split-thickness skin was 
placed dermal-side down on a 0.25% trypsin (Difco Laboratories, 
Detroit, MI)/PBS solution for 60 min at 37~  Epidermal sheets 
were peeled from the underlying dermis and transferred to washing 
medium (WM: RPMI 1640 [Gibco Ltd., Paisley, Scotland] sup- 
plemented with 10% heat-inactivated FCS [Flow Laboratories, Ltd., 
Ayrshire, Scotland],  2 mM t-glutamine [Flow Laboratories],  and 
an antibiotic-antimycotic solution [Gibco Ltd.] consisting of 100 
/~g/ml penicillin,  100/~g/ml streptomycin, and 0.25 #g/ml fungi- 
zone) containing 0.025%  deoxyribonuclease  I (Sigma Chemical 
Co., St. Louis, MO), After 20-30 min at room temperature,  the 
sheets were vigorously stirred,  and the resulting cell suspension 
(viability, 70-90% by trypan blue exclusion) was passed through 
gauze to remove large cell dumps. 
LC-enriched  Epidermal CellSuspensions.  Single epidermal cell sus- 
pensions  were resuspended in DME (Flow Laboratories)  and in- 
cubated for 45 rain at 37~  on collagen (Vitrogen 100; Collagen 
Corp., Palo Alto, CA) -coated petri dishes resulting in the preferen- 
tial attachment of  basal keratinocytes. Since differentiating keratino- 
cytes are more susceptible to osmotic shock treatment than other 
epidermal cells, nonadherent cells were agitated for 1 min in a hypo- 
tonic PBS/distilled H20 (8/2) solution. Dead cells (",80%) were 
removed by Lymphoprep (Nyegaard,  Oslo, Norway) density gra- 
dient centrifugation; the interface  cells were then collected  and 
resuspended in WM. The viability of this cell suspension was reg- 
ularly ~>90%, and the quality of LC enrichment ranged between 
20 and 70% as determined by FITC-OKT6 immunostaining.  These 
cells were either used for immunolabeling or RNA isolation. 
LC-depleted Epidermal Cell Suspensions.  1.5-2  x  107 unfrac- 
tionated epidermal cells were resuspended in 5 ml ice-cold WM 
containing 0.5/~g/ml anti-HLA-DR mAb (Becton Dickinson & 
Co. (BD),  Sunnyvale, CA). Cells were incubated for 30 min on 
ice, washed, and resuspended in 5 ml PBS/1% FCS. This cell sus- 
pension was incubated with 50 #1 goat anti-mouse IgG covalently 
bound to magnetic polystyrene beads (Dynabeads  M-450; Dynal 
A. S., Oslo, Norway) under constant rotation for 1 h at 4~  Cells 
attaching to the beads were pelleted by application of a magnetic 
field; nonadherent cells (viability, 70-90%; ~0.05% CDla + cells) 
were collected,  washed,  and processed for RNA extraction. 
Dermal Cell Suspensions.  Split-thickness  skin from which the 
epidermis had been removed by either dispase or trypsin separation 
was exposed to 0.5% trypsin/PBS for 10 min at 37~  Loosened 
cells were then freed by mechanical agitation, collected, washed, 
resuspended  in WM, and processed for RNA extraction. 
Cell Lines.  Mouse myeloma cells SP 2/0 Ag 14 and Chinese 
hamster ovary (CHO) cells were obtained from the American Type 
Culture Collection (Rockville, MD). A T cell hybridoma lacking 
the ~'chain of the TCR (2M2) was a gift of Dr. R. Klausner (Na- 
tional Institutes of Health). The EBV-transformed B cell line RPMI 
8866 was provided by Dr. K. Ishizaka (Johns Hopkins University, 
Baltimore,  MD);  the KU812 cell line, a leukemic cell line with 
basophilic characteristics,  was a gift from Dr. K. Kishi (Depart- 
ment of Internal Medicine, Niigata University School of Medicine, 
Niigata, Japan). 
Transfectants 
Stable transfectants  secreting soluble human oe chain products 
have been described elsewhere (9). Stable transfectants  expressing 
surface FceRIoe~r complexes were obtained by cotransfecting CHO 
cells or 2M2 cells with human FceRIcz and 3, chain cDNAs using 
methods similar to those described previously for the transient ex- 
pression  of human FceRI in  COS  cells (10). Briefly, the cells 
(10Vml) were electroporated  at 260 V, 500/iF for introduction 
of the following DNAs (100/~g/ml total): human ce chain cDNA 
in pCDL-SRcr  (a gift from K. Arai, DNAX, Palo Alto, CA; 
11) and human y chain cDNA in pBJIneo (a gift from M. Davis, 
Stanford, CA; 12). The cells were then allowed to recover and placed 
in Iscove's medium for 2 d before the addition of 500 #g/ml ne- 
omycin. Resistant cells were selected for expression of FceRI using 
FITC-IgE and FACS  |  (Becton Dickinson & Co.). 
Antibodies 
Key antibody reagents are listed in Table 1. With the exception 
of the two anti-FceRIcx mAbs, all were obtained from commercial 
sources. 
Production of mAbs against the Human FceRIcr Chain.  BALB/c 
mice were immunized intraperitoneally at 2-wk intervals with 5 
x  106 transfected  CHO cells expressing  surface FceRIocy com- 
plexes. 3 d after the fourth immunization, a single spleen cell sus- 
pension was prepared from the immunized mice and fused to the 
mouse myeloma cell line SP 2/0 Ag 14 as described (13). Hybridoma 
supernatants were screened for antibodies binding to oe/y-transfected 
CHO cells. Hybridomas secreting antibodies binding to untrans- 
fected CHO cells were eliminated. Antibody binding to CHO cells 
was analyzed by FACS  |  after incubation with FITC-conjugated 
goat anti-mouse IgG. Several reactive clones were obtained and 
subcloned three times by limiting dilution. Two stable producer 
clones designated  15-1 (IgGl,k) and 19-1 (IgG2a,k) were further 
characterized.  The two mAbs were purified by using kits (Pierce 
Chemical Co., Rockford, IL) according to the manufacturer's in- 
structions. 
Single-labeling Immunostaining  Procedures 
IgE as well as anti-FceR mAb binding to the cellular substrate 
was visualized with a streptavidin-biotin-peroxidase  (ABC) tech- 
nique as previously described  (14). 
IgE-binding Assay.  Cryostat sections were incubated overnight 
with one of the IgE preparations  (Table 1) at 4~  Sections were 
then exposed to biotinylated goat anti-human IgE for I h at room 
temperature,  washed, and incubated with ABC as indicated by the 
manufacturer  (Dakopatts).  Finally,  sections  were  reacted  with 
3-amino-9-ethylcarbazole  (Sigma Chemical Co.) in 0.05 M acetate 
buffer, pH 5.0,  for 5-10  min, washed,  and counterstained with 
hematoxylin. 
In other experiments,  bound IgE was detected by exposing the 
sections to one of the mouse anti-human IgE mAbs (Table 1), fol- 
lowed by consecutive incubations with a 1:100 diluted biotinylated 
sheep F(ab')2 anti-mouse Ig (Amersham, Buckinghamshire, UK) 
and ABC. For control purposes, we either omitted the IgE incuba- 
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Reagent type  Reagent name  Species/isotype  Concentration  Working dilution  Source 
Ig preparations  IgE (myeloma,  Human  2 mg/ml  1:20,000-200" 
semi-purified) 
IgE (serum,  Human  2 mg/ml  1:200" 
semi-purified) 
Chimeric  Human IgE  Mouse/human  1 mg/ml  1:100" 
(anti-NP)  monoclonal 
purified protein 
IgG (serum)  Human  13 mg/ml  1:1300" 
Anti-human  Ig  Anti-human  IgE mAb  Mouse IgG1  1:100" 
(DAKO-IgE) 
mAb anti-IgE  Mouse IgG2a  1:100" 
(D~I) 
mAb anti-IgE  Mouse IgG1  1:100" 
(De2) 
Biotinylated  Goat Ig  1:20" 
anti-human  IgE 
Biotinylated  Goat Ig  1:20 
anti-human  IgG 
Anti-FceRIc~  15-1  Mouse IgG1  280/~g/ml  1:200",1:40' 
19-1  Mouse IgG2a  75 #g/ml  1:60",  1:10' 
Anti-FceRII/CD23  BU 38  Mouse IgG1  1:500" 
TO  1  Mouse IgG3  1:50" 
Anti-Fc'yRII/CD32 
MHM 6  Mouse IgG1  1:50",  1:50' 
BB 10  Mouse IgM  1:100" 
IOB8  Mouse IgG1  1:100" 
HD50  Mouse IgG2b  1:100" 
Leu 20  Mouse IgG1  1:100" 
BSL/23  Mouse IgG1  1:100" 
IV.3  Mouse IgG2b  1:40' 
Chemicon 
(Temecula,  CA) 
Chemicon 
Serotec 
(Oxford,  UK) 
Chemicon 
Dakopatts 





Inc.  (Burlingame,  CA) 
Vector Laboratories,  Inc. 
Binding  Site Ltd. 
(Birmingham,  UK) 
Cymbus Bioscience Ltd. 
(Southampton, 






(Hialeah,  FL) 
Becton Dickinson  & Co. 
Serotech 
Medarex  (West 
Lebanon,  NH) 
* Staining. 
* Blocking. 
tion step or replaced it with IgG. In addition,  we controlled  the 
purity of the IgE preparations by reacting  the IgE-exposed sec- 
tions with goat anti-human  IgG. 
For IgE-binding inhibition studies, cryostat sections were preex- 
posed to various anti-FcR mAbs (15-1 [7/zg/ml];  19-1 [7.5/zg/ml]; 
MHM6 [8.8/zg/ml];  IV.3 [25 ~g/mll; Table 1) for 4 h at room 
temperature before the IgE-binding  assay. To determine whether 
the IgE-binding  protein  (eBP), a D-galactose-binding lectin  (15, 
16), is involved in the binding oflgE to skin cells, IgE preparations 
were premixed with 100 mM s-lactose (Sigma Chemical Co.) be- 
fore use in the assay. 
Binding Studies with anti.FceR mAh  Cryostat sections of normal 
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sheep serum/PBS for 30 min at room temperature, washed, and 
incubated overnight at 4~  with one of each of the appropriately 
diluted (in PBS/5% BSA) anti-FceRI and anti-FceRII mAbs listed 
in Table 1. Substrates were then washed and exposed to a 1:100 
diluted biotinylated F(ab')z sheep anti-mouse Ig (Amersham) for 
I h at room temperature, washed, and subjected to the ABC tech- 
nique. Controls included the omission of the primary antibody or 
its replacement with irrelevant, isotype-matched mAb. 
Double-labeling Immunostaining  Procedures 
Characterization of lgE-binding Epidermal Cells.  Cryostat sections 
were incubated overnight at 4~  with one of  each of  the IgE prepa- 
rations (Table 1), washed, and incubated  consecutively  for 1 h periods 
at room temperature with: (a) biotinylated goat anti-human IgE 
(Table 1), (b) Texas red-streptavidin (1:50; Zymed Labs, Inc., San 
Francisco, CA), and (c) FITC-labeled anti-CDla (OKT 6;  1:10; 
Ortho Diagnostic Systems Inc., Raritan, NJ). The sections were 
mounted and viewed with a fluorescence  microscope (Axiophot; 
Carl 7_eiss, Inc., Oberkochen, FRG) using appropriate filter settings. 
Identification of IgE-bearing Dermal Mast Cells.  IgE-exposed 
cryostat sections were reacted with mouse anti-human IgE/D,2 
mAb (1:20) followed by a 1:20 diluted rhodamine-conjugated goat 
F(ab')~ anti-mouse  IgG (Immunotech) and counterstained with 
FITC-avidin (1:50; Zymed Laboratories) (17). 
Characterization of Anti-Fc~Rl-reactive Epidermal Cells.  Cryostat 
sections were labeled with anti-FceRIc~ mAb (Table 1) using the 
ABC technique. After PBS washes, the substrates were incubated 
at room temperature with 10% normal mouse serum in PBS for 
30 rain and counterstained with FITC-OKT6  (1:10) for 1 h. 
Additionally, we searched for surface expression of FceP,  Icr on 
LC by two-color flow cytometry. LC-enriched epidermal cell sus- 
pensions were preincubated  with human gamma globulin (5 mg/ml; 
Beriglobin S; Behring, Marburg, FRG), and were then incubated 
with either mAb 15-1, OKT6, or with an irrelevant control mAb 
(all purified IgG1; 10 #g/ml). Thereafter, cells were reacted with 
affanity-purified,  biotinylated goat anti-mouse IgG1 (5/zg/ml; gift 
of Dr. W. Knapp, Institute of Immunology, University of Vienna 
Medical School, Austria) followed by streptavidin-PE (BD). All 
samples were then exposed to FITC-anti-HLA-DIL (2.5/~g/ml; 
BD). Flow cytometric  analysis  was performed  on a FACScan  |  (BD). 
List mode data of 104 epidermal ceils gated for HLA-DR positivity 
were recorded and individual histograms displayed  as cell number 
versus PE fluorescence  intensity. 
Identification of FceRI-bearing Dermal Mast Cells.  After an over- 
night incubation with the anti-FceRIct mAb, sections were reacted 
with rhodamine-conjugated goat F(ab')z anti-mouse  IgG (1:20, 
Immunotech) and counterstained with FITC-avidin (1:50). 
Immunoelectronmicroscopic Studies 
10-15-#m cryostat sections of PLP-fixed tissue were subjected 
to  an  immunogold  staining  procedure using  the  diffusion 
("preembedding") method (18). Briefly, sections were quenched 
in  PBS/1% egg albumin (EA; Sigma Chemical Co.)/0.005% 
saponin (Sigma Chemical Co.; 19) and then incubated with mAb 
15-1 (1:20 in  PBS/1% EA/0.005%  saponin) for  12 h  at 4~ 
After washing, the sections were reacted with a 1:5 diluted goat 
anti-mouse IgG-gold conjugate (5 nm; Amersham), washed, and 
fixed with 1.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 
7.4. After incubation in veronal acetate-buffered  osmium and 0.5% 
aqueous uranylacetate,  the sections were dehydrated  and embedded 
in Epon 812. In control experiments, the mAb 15-1 was replaced 
by an isotype-matched  anti-vimentin  mAb (1:10; Dakopatts). Ultra- 
thin sections were cut on an "Ultracut" ultramicrotome (Reichert 
Scientific Instruments, Buffalo, NY) and examined with an elec- 
tron microscope (1200 XL; Jeol, Tokyo, Japan). 
RNA  Preparation and PCR 
Total cellular RNA was extracted from unfractionated, LC- 
enriched, and LC-depleted epidermal cells, as well as from dermal 
cells, cell lines, and from  a full-thickness skin specimen with 
guanidinium thiocyanate  followed  by centrifugation  through a CsCI 
cushion as described (20). 
For cDNA synthesis, 2/~g of KNA was denatured at 65~  for 
5 rain, chilled on ice, and reverse transcribed in a 20-/~1 reaction 
volume containing lx buffer, 10 mM DTT, 300 U Moloney mouse 
leukemia virus (MMLV) reverse transcriptase (all Gibco-Bethesda 
Research Laboratories, Gaithersburg, MD), dNTPs (0.5 mM each), 
0.5 #1 RNase inhibitor, and 0.5 #1 dT15 (1/~g/ml) (all Boehringer 
Mannheim Biochemicals), incubated at 37~  for 90 min, boiled 
for 5 rain, and stored at 4~ 
PCR. was carried out using 1 ~1 cDNA mix in 50-/~1 reaction 
volume containing lx  buffer (Clontech, Palo Alto, CA), dNTPs 
(0.2 mM each; Boehringer Mannheim Biochemicals), 0.4/~M 3' 
and 5' primers, and 1.5 U Amplitaq DNA Polymerase  (Cetus Corp., 
Norwalk, CT). Samples  were overlaid  with 50 #1 mineral oil (U.S. 
Biochemical Corp., Cleveland, OH) and cycled in an Intelligent 
Heating Block (Hybaid, Teddington, UK) 1 rain at 94~  2 rain 
at 60~  and 3 rain at 72~  for the indicated numbers of cycles. 
20 ~1 of this reaction product was then run on a 1.5% agarose 
gel and transferred to Nytran N membranes (Schleicher  & Schuell, 
Inc., Dassel, FRG). Blots were prehybridized and hybridized at 
68~  as suggested by the supplier. The hybridization probe was 
a sequence-specific  oligonucleotide (2 pM) that had been 3' labeled 
with terminal transferase  (Boehringer  Mannheim Biochemicals)  and 
2.5/~1 ~[32p]dATP (3,000 Ci/mM; Amersham Corp.). After sev- 
eral washes (final stringency, 0.5% SDS/lx SSC, 55~  the blots 
were exposed to Kodak XAR5 film  in the presence of  intensifying 
screens at  -70~  for 12 h. 
The 3-actin primers were purchased from Clontech; other oli- 
gonucleotides  were synthesized  on a Cyclone Plus synthesizer  (Mil- 
ligen, Burlington, MA) following the manufacturer's instruction, 
and controlled for the absence of degradation by PAGE. Sequences 
(21-24; J.-P. Kinet, manuscript in preparation) are listed in Table 2. 
Results 
Demonstration of IgE-binding  Cells in  Cryostat Sections of 
Normal Human  Skin.  When cryostat sections of normal 
human skin from 12 nonatopic donors were incubated with 
various IgE preparations (Table 1) and then reacted with ei- 
ther monoclonal or polyvalent anti-IgE in an indirect im- 
munoperoxidase technique, we regularly observed numerous 
stained cells in both the epidermis and dermis (Fig.  1 A). 
The staining intensity was dependent upon the IgE concen- 
tration. Optimal results were obtained with 10 or 5/~g/ml, 
but positive cells were still detectable at 1/~g IgE/ml. Posi- 
tive cells were not discernible at 0.I/~g IgE/ml. Labeled cells 
within the epidermis were dendritic in shape and mainly lo- 
cated in a suprabasal position (Fig. 1 A). Stained cells within 
the dermis were scattered throughout this tissue with a ten- 
dency to form clusters  around the microvasculature (Fig.  1 
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Expected 
Gene  fragment  Sequence  Reference 
FceRI, c~ chain  536 
5' Primer 
Y  Primer 
Internal 
FceRI, /~ chain  446 
5' Primer 
3' Primer 
FceRI, y  chain  338 
5' Primer 
3' Primer 
Tryptase  531 
5'  Primer 
3' Primer 
CD23  (FceRII)  365 
5'  Primer 
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Figure 1.  Presence  of IgE-binding cells within the epidermis and dermis of normal human skin. (A) Detection of stained cells in both the epidermis 
and dermis after exposure of a cryostat section of normal human skin to monomeric human IgE (5 #g/ml) followed  by incubation with goat anti-human 
IgE in an indirect immunoperoxidase technique. (B) Absence of labeled cells in a cryostat serial section when the anti-IgE reagent was replaced by 
goat anti-human IgG. 
1357  Wang et al. A). No labeled cells were seen when the IgE incubation step 
was either omitted, substituted for by IgG, or followed by 
the incubation with the anti-IgG reagent (Fig.  1 B). 
To determine the nature of IgE-binding skin cells, im- 
munofluorescence double-labeling studies were performed on 
all  biopsies.  We  found that  the  IgE-binding cells  in  the 
epidermis uniformly displayed anti-CDla reactivity and, thus, 
represent LC (data not shown). Enumeration of IgE § and 
CDla § cells in 8-10 sequential high-power fields of one sec- 
tion of each biopsy specimen revealed that 45-79%  (mean, 
64%  _+  9% SD) of CDla-positive cells bound IgE. Within 
the dermis,  some IgE-binding cells, predominantly in the 
deeper part of this tissue,  were FITC-avidin reactive  (data 
not shown) and, thus, represent mast cells (17). IgE-binding 
cells around the microvessels  of the papillary dermis were 
mostly FITC-avidin negative (data not shown). 
Anti-FcERIot Chain mAbs.  We have generated and charac- 
terized two mAbs, denoted 15-1 and 19-1, against the ct chain 
of FceRI. These mAbs react with CHO transfectants ex- 
pressing Fcetkloty complexes  on their surface but not with 
nontransfected CHO cells. They also react specifically with 
mouse T cells (2M2) stably transfected with human FceRIo~ 
and "y chains and express surface ot/y complexes (Fig. 2). Fur- 
thermore, the two mAbs reacted strongly and specifically in 
an ELISA with soluble human o~ chain purified on an IgE- 
Sepharose  column (data not shown). Taken together, these 
results indicate that both mAbs react with the o~ chain of 
FceRI. The binding of monomeric IgE to the surface-expressed 
o~ chain can be completely inhibited with mAb  15-1 (Fig. 
3 B),  indicating that the epitope corresponding to  15-1 is 
close to, or even identical to, the receptor binding site for 
IgE. By contrast, 19-1 only slightly inhibits the binding of 
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Figure  3.  mAb 15-1, but not 
mAb 19-1, competitively  inhibits 
the binding of mouse IgE  to 
Fceklc=/~' transfectants. Human 
FceRIct3,-transfected  CHO cells 
were preincubated with either 1 
t~g/ml mouse  IgG (.4), 1/zg/ml 
mAb 15-1 (B), or 1/~g/ml mAb 
19-1 (C), then reacted with 10 
/~g/ml FITC-conjugated  mouse 
IgE (  .......  ) and then sub- 
jected to FACS  |  analysis.  As con- 
trols, the results obtained after 
preincubation  with 100/~g/ml  of 
mouse IgE (  ) or medium 
alone (  .......  ) are shown in 
each panel. 
IgE under the same conditions (Fig. 3 C). This may either 
indicate that the antibody has an affinity too low to compete 
with IgE, or that it is directed against an epitope unrelated 









15-1  19-1 
5o ~.  CHO 
40 
"  II  . 
|  :'. 
20  ~  ..." "... 
l, 
0  '  '  ;'"'1  '  '~ ""'1  '  '  'r'"'l 
10  0  101  102  103 
i  CliO 
-'~ 
'"'"1  ,  ,  NIm i  ,  ,  ,,,,1, I 







5O  2M2  2o3O401A..I 
,o  ,",ii:: 
0  1  "'''t  '  '""'I 
10  o  101  102  103 
50  -~  2M2 
40-~ 
20 
10  "'"'...,,.,. 
...... i  0  ........  I  ......  ~1  ........  I  ........  I 
104  100  101  102  103  104 
Fluorescence  Intensity 
Figure  2.  mAbs 15-1 and  19-1 react with human 
FceRIc~/3' transfectants. Human FcEKlt~y-transfected 
(  .......  ) or nontransfected (  .......  ) CHO and 
2M2 cells were incubated  with either mAb 15-1 or mAb 
19-1. Cells were then stained with FITC-labeled goat 
anti-mouse IgG and subjected  to FACS  |  analysis.  As an 
additional control, t~/3' transfectants  were reacted with 
FITC-conjugated goat anti-mouse IgG only (  ). 
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ditions  (see Fig.  3  C). 
Anti-FceRIot  mAb  15-1  Prevents IgE  Binding  to  Skin 
Cells.  To identify the nature of the IgE-binding structure 
on  skin cells,  we preincubated the sections with reagents 
known to prevent cellular Ig binding. We found that neither 
lactose nor the mAbs MHM6 or IV.3 interfere with the ob- 
served IgE binding.  Thus,  it is unlikely that eBP,  FceRII, 
or Fc3'RII are responsible for the binding of monomeric IgE 
to skin ceils. In sharp contrast, the anti-FceRIot mAb 15-1, 
but not the mAb 19-1, completely inhibited IgE binding to 
epidermal cells and nearly completely to dermal cells (Fig. 
4, A  and B). 
Anti-FceRIcr mAt~ but Not Anti-FceRII Reagents, Bind to 
Epidermal Langerhans Cells.  When we screened cryostat skin 
sections from 12 nonatopic healthy donors for the presence 
of FcdLII/CD23 + cells with a panel of eight appropriate re- 
agents (Table 1), both the epidermis and the dermis were con- 
sistently devoid of stained cells  (data not shown).  In con- 
trast, both anti-FceRIc~ mAbs regularly gave a staining pattern 
similar to that seen in our IgE-binding studies. As exemplified 
by 15-1 immunolabeling on cryostat sections, FceRIot-positive 
dermal ceils were mostly found around the dermal microvas- 
culature (Fig.  5, A  and B) and were occasionally scattered 
between collagen bundles.  Some of these cells were FITC- 
avidin reactive, thus representing mast cdls (data not shown). 
Within the epidermis, FcdLIot-positive ceils exhibited typ- 
ical LC morphology and topography (Fig. 5, A and B). Their 
dendritic configuration could be even better appreciated on 
epidermal sheet  preparations  (Fig.  5,  C  and D).  Double- 
labeling experiments on cryostat sections demonstrated that 
all FceRIc~-positive epidermal cells are CDla positive, which 
confirms their LC nature. Conversely, we found that the vast 
majority ('~80%) of CDla-bearing epidermal cells displayed 
anti-FceRIot reactivity (data not shown). 
Additionally,  flow  cytometric  analysis  of LC-enriched 
epidermal  cell  suspensions  subjected  to  a  two-color  im- 
munolabeling procedure revealed that mAb 15-1 reacts with 
the surface of HLA-DR/CDla coexpressing epidermal cells 
(Fig.  6). In concordance with these data, immunoelectron- 
microscopic studies showed that LC with their characteristic 
Birbeck granules are the only anti-FceRIot-reactive epidermal 
cells as evidenced by the discontinuous and patchy distribu- 
tion of 5-nm gold particles along their surfaces (Fig.  7 A). 
In contrast, the isotype-matched anti-vimentin mAb reacted 
exclusively with cytoplasmic 10-nm filaments present in LC 
and melanocytes (Fig.  7 B). 
Presence of  FceRIcr, ~, and T Chain Transc@ts  in LC-enriched, 
but Not in l..C-depleted, Epidermal Cell Suspensions.  Further 
attempts to identify the IgE-binding structure on LC included 
the search for FcdL gene expression by skin ceils. Total cel- 
lular RNA from various cell and tissue preparations was re- 
verse transcribed into cDNA (see Materials and Methods); 
cDNA equivalent to 100 ng total cellular ILNA per sample 
was used and regularly yielded bands  of the expected size 
when subjected to PCR with/~-actin primers (Fig.  8 A). 
This indicates that each sample contains cDNAs of  comparable 
quality. 
Although anti-FceRII/CD23 mAb immunolabeling studies 
yielded negative results on LC, FceRII/CD23 might be present 
Figure 4.  Anti-FceRIo~  mAb 15-1 inhibits IgE binding to skin cells. Cryostat  serial sections  of normal  human skin were  preincubated  with either 
mAb 15-1 (A) or mAb 19-1 (B), then exposed to monomeric  human IgE, and then reacted  with biotinylated  goat anti-human IgE in an indirect 
immunoperoxidase  technique.  Preincubation  of sections  with mAb 15-1 (A) but not with mAb 19-1 (B) abolishes  the IgE-binding  capacity  of epidermal 
and dermal cells, x400. 
1359  Wang  et al. Figure 5.  Demonstration of FceRJrv-positive cells in cryostat  sections and epidermal sheet preparations  of normal  human skin. Cryostat sections 
(.4  and B) or epidermal  sheet preparations  (C and D) were subjected to either  mAb 15-1 (,4  and C) or to an irrelevant isotype-matched  antibody 
(B and D) in an indirect immunoperoxidase technique. Within the dermis, most 15-1-reactive  cells are associated with the microvascuhture  (A). Within 
the epidermis, 15-1-positive cells are predominantly  located at a suprabasal position  (A) and exhibit a pronounced dendritic  shape (A and C).  x  400. 
on LC surfaces  in either minute quantities and/or in a configu- 
ration inaccessible  to  these mAbs.  Thus, we searched  for 
FceRII/CD23 mRNA in the various cell preparations using 
a pair of primers that recognize both alternatively spliced CD23 
species (25) and span an intron (26).  After 30 PCR cycles, 
strong bands were generated from RPMI 8866 and slightly 
weaker bands from KU812 (Fig. 8 B).  In contrast, all skin 
cell samples were negative (Fig.  8 B).  10 additional cycles 
yielded very faint bands in  two of the four LC-enriched 
epidermal cell preparations, and a more pronounced band was 
yielded in the sample of human foreskin (data not shown). 
Unffactionated and LC-depleted epidermal cell preparations 
gave negative results (Fig. 8 B). These data make it very un- 
likely that FceRII/CD23 is a relevant structure for IgE binding 
to LC. 
We  next  searched  for  the  expression of FceRIoe chain 
mRNA in the various samples. As expected, we found strong 
signals of the appropriate size in KU812, but not in RPMI 
8866, using 25 PCR cycles  with FceR.Iot  chain-specific primers 
(Fig. 8 C). PCR amplification of eDNA from I_C-enriched 
1360  FceRI-mediated  IgE Binding  by Epidermal  Langerhans Cells Figure 6.  Flow cytometric analysis of FcERIot surface expression  on epidermal cells gated for HLA-DR positivity. Overlay histograms represent 
the reactivity of HLA-DR-positive epidermal cells with either medium alone (dark blue), with an irrelevant  IgGl control mAb (green), with the anti- 
FceRlct mAb 15-1 (shaded red plot),  or with the mAb OKT6  (cyan); mAb binding is visualized by biotinylated goat anti-mouse IgG1 followed by 
streptavidin-PE, and the logarithmically  amplified PE fluorescence intensity is plotted on the abscissa. The homogeneous CDla expression of the HLA- 
DR-positive cells confirms  their LC nature  (cyan). 
epidermal cell suspensions from four donors yielded bands 
of equal size and comparable intensity to those seen in the 
KU812 cell line. Such amplification products were also gener- 
ated from various dermal and crude epidermal cells, but not 
from LC-depleted epidermal cells (Fig. 8 C). Note that within 
a  given  donor  the  intensity of signals  from LC-enriched 
epidermal cells was regularly stronger than those from dermal 
cell samples (containing mast cells) and far exceeded those 
generated from unfractionated epidermal cells (Fig. 8 C). This 
pattern of gene expression was entirely reproducible  in five 
independent experiments.  Our contention that the observed 
bands represent FceRIot chain-specific mRNA was proven 
by the findings that: (a) omission of reverse  transcriptase  yielded 
no signal (data not shown);  (b) the pair of primers spans an 
intron (J.-P. Kinet, unpublished observation);  and (c) the 
blotted band hybridized with an internal oligonucleotide under 
stringent conditions (Fig. 8 D). These data strongly suggest 
that I.C, but no other epidermal cells, contain Fceglot chain 
transcripts. However, could a few mast cells putatively present 
in LC-enriched, but not in LC-depleted, epidermal cell sus- 
Figure 7.  Ultrastructural localization of anti-FceRIc~-reactive moieties on the surface of LC. Saponin-treated cryostat sections of PLP-fixed normal 
human skin were incubated with either mAb 15-1 or an isotype-matched anti-vimentin mAb in an indirect immunogold-labeling technique and then 
processed for ultrastructural examination. The 15-1 reactivity of LC (identified by its characteristic Birbeck granules)  (arrows) is evidenced by the patchy 
and discontinuous distribution of 5-nm gold particles on its surface (A). In contrast, anti-vimentin staining results in the selective decoration of LC 
intermediate-sized filaments  with the gold particles (B).  xS0,000;  bars,  0.2 #m. 
1361  Wang et al. mast cells as the source of the observed ot chain expression 
in  the  LC-enriched  samples. 
In  mast  ceils,  FceRI  is  expressed  as  a  heterotetrameric 
holoreceptor consisting of one ~, one/3,  and two 3' chains 
(28).  In transfectants,  ot and 3' chains suffice for surface ex- 
pression of a high  affinity IgE binding  site (9).  This raises 
the question whether expression of FceRIot,/3, and 3' chain 
mRNA are linked in cells other than mast cells and basophils. 
The/3  chain  has  recently been sequenced,  and its genomic 
organization was determined (J.-P. Kinet, manuscript in prep- 
aration).  Using appropriate  amplification  either from oligo(dt)- 
primed cDNA or from cDNA generated with a chain-specific 
3' primer,  we readily detected FceRIB chain mRNA in KU812 
cells  and  dermal  ceUs whereas  only  trace  amounts  were 
identified  in  LC-enriched  epidermal  cell  samples.  Unfrac- 
tionated  and  LC-depleted  epidermal  ceils  were  devoid  of 
FceRI~ chain mRNA  (Fig.  8 F).  These data indicate  that 
the regulation  of the FceRIB chain in LC may differ from 
that  in mast cells.  In contrast,  we found that  the 3' chain 
mRNA expression pattern closely follows that of the c~ chain, 
suggesting coordinate regulation of expression in both mast 
cells  and  IX= (data  not  shown). 
Figure 8.  Demonstration  of FceR.I~  chain mR.NA  in LC-enriched, but 
not in l_C-depleted,  epidermal  cells  from four different  donors. Oligo(dT)- 
primed cDNA equivalent  to 100 ng total cellular RNA was obtained  from 
cell lines RPMI 8866 and KU812, from various skin cell preparations, 
and from a sample  of human foreskin. Subsequent  PCR amplification  was 
carried out for the indicated number of cycles  using sequence-specific  3' 
and 5' primers. The reaction product was then run on a 1.5% agarose 
gel. In the case  of the FceRl~ chain, it was blotted onto Nytron N mem- 
branes and hybridized with an internal oligonucleotide as described in 
Materials and Methods. (A) B-actin, 30 cycles; (/3) CD23, 30 cycles; (C) 
FceRlc~ chain, 25 cycles; (E) tryptase, 30 cycles; (F) Fc~RIB chain, 35 
cycles. The Southern blot of C is shown in D. 
pensions account for the observed FcERIot chain mRNA ex- 
pression in the LC-containing epidermal cell samples? To test 
this possibility, PCR was carried out for tryptase, an enzyme 
that,  among skin cells,  is considered to be specific for mast 
cells (27). As shown in Fig. 8 E, tryptase expression is confined 
to the dermal cell compartment, thus excluding contaminating 
Discussion 
This  study  demonstrates  that  the  majority  of resident 
epidermal LC are capable of binding monomeric IgE. When 
designing experiments to define the structure responsible for 
this phenomenon, we considered four candidates:  (a) The tetra- 
meric FceRI, which binds both homologous and heterolo- 
gous monomeric IgE with high affinity (28); (b) the single- 
chained FcERII, which binds IgE with an ~ 100 times lower 
affinity than  FceRI (24,  29,  30);  (c) the  EBP, a /3  galacto- 
side-specific lectin  originally  described in  a rat  basophilic 
leukemia cell line (15, 16); (d) the single-chained FeyRII/CD32 
with its polymorphic cytoplasmic tail,  which binds mono- 
meric IgG with very low affinity (28) and which appears to 
be the only FcyR  species expressed by epidermal Langerhans 
cells  (31). 
Concerning the last candidate, we were originally  concerned 
that the binding of the various IgE preparations to LC could 
be due to trace amounts of IgG putatively present in these 
preparations.  However, LC staining was not seen when in- 
cubation of the sections with IgE was either substituted for 
by IgG or followed by incubation with anti-IgG.  Addition- 
ally,  since murine Fc'yRII are capable of binding IgE (J.-p. 
Kinet, unpublished results), we preincubated sections with 
mAb IV.3 directed against the IgG-binding site of CD32 (32). 
This preincubation step did not prevent IgE binding to LC, 
a strong argument against the possibility that IgE binds human 
LC via Fc3,RII. 
Various human myeloma IgE proteins known to be exten- 
sively sialylated react with human eBP only when they are 
pretreated with neuraminidase (16). In the case of polyclonal 
serum  IgE, there is individual  variation  in  the proportion 
of IgE recognized by eBP depending on the degree of sialyla- 
tion of different IgE oligosaccharides (33). Our study shows 
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that the latter binding cannot be competitively blocked by 
lactose. Thus, we conclude that eBP is of little or no rele- 
vance for LC IgE binding. 
A body of evidence strongly argues against the involve- 
ment of FceRII/CD23  in  the binding  of IgE to  resident 
epidermal LC.  First,  binding was not blocked with mAb 
MHM6, which readily inhibits IgE-binding to normal B cells, 
B cell lines, and promonocytic cell lines (34; A. Rieger, un- 
published  observations).  Second,  we  failed  to  detect  any 
epidermal cell immunostaining when cryostat sections of 
normal human skin were exposed to eight anti-CD23 mAb 
recognizing different epitopes of this molecule. Although this 
observation suggests that LC in situ do not bear FcERII/CD23 
moieties,  our  PCR  studies,  as  well  as  immunoelectron- 
microscopic studies by Torresani et al. (35), indicate that freshly 
isolated LC, or at least a subpopulation thereof, express minute 
quantities of this molecule. Since it is conceivable that the 
perturbance of the epidermal milieu required for the prepa- 
ration of single epidermal cell suspensions might trigger events 
resulting in CD23 gene expression, one cannot safely con- 
clude that the extremely weak CD23 expression by freshly 
isolated LC is representative of the in situ situation. 
Our data are in excellent agreement with the notion that 
the binding of monomeric IgE to epidermal I_C is mediated 
by the high affinity IgE receptor, FceRI. Strong support for 
this assumption came from studies with the mAbs 15-1 and 
19-1. By FACS  |  these reagents react specifically with CHO 
and mouse T cell transfectants expressing FceR.Io~y  complexes 
on their surfaces, and by ELISA, these mAbs bind strongly 
and  specifically  to  soluble  human  FcERIcr  Competitive 
binding studies revealed that mAb 15-1, which interferes with 
IgE binding to the FceRIc~ chain expressed on the surface 
of FceRIoo' transfectants, completely inhibits the binding 
of IgE to LC in cryostat sections of normal human skin. Con- 
versely, mAb 19-1, which only slightly inhibits IgE binding 
to the transfectants, failed to prevent IgE binding to LC. Fi- 
nally, light and electron microscopic immunolabeling studies 
with mAbs 15-1 and 19-1 provided direct evidence for the 
presence of FcERIcr on the surfaces  of LC,  but  no other 
epidermal cells. 
The restricted availability of large specimens of human skin 
has impeded our efforts to immunochemically characterize 
the Fc receptor for monomeric IgE on LC.  The detection 
of specific transcripts for the various Fc~RI chains in RNA 
from LC-enriched epidermal cell suspensions indicates that 
it is a multimeric complex composed of the same polypep- 
tide chains as the FcERI ofbasophils and mast cells (28). Our 
additional finding that  the relative level  of FcERI3 chain 
mRNA in LC-enriched epidermal cell suspensions appears 
to be lower than in dermal cell suspensions may simply be 
attributable to differences in amplification effciency. Alter- 
natively, the Fc receptor for monomeric IgE on LC might 
occur in two configurations: one form identical to that found 
on mast cells and basophils,  and the other form consisting 
only of ce and y  chains. 
This study demonstrates for the first time that LC and cer- 
tain dermal dendritic cells predominantly located around the 
dermal microvasculature (36) in healthy human skin can bind 
monomeric IgE via FceRIc~. An important question remains: 
Does a similar receptor-ligand interaction also occur in patho- 
logic situations in which IgE binds in vivo to LC and other 
dendritic cells, e.g. AD (1-4)? Recently, we performed IgE- 
binding studies on acid-treated cryostat sections of lesional 
skin from one AD patient.  This treatment successfully re- 
moved in vivo bound IgE. Incubation of these acid-treated 
sections with monomeric human IgE again led to LC anti- 
IgE reactivity, which could be blocked by the anti-FceRIoe 
mAb 15-1 (Wang et al., unpublished observations). Should 
this finding be confirmed with a larger number of AD pa- 
tients, it would support the concept that FceRI is the critical 
and biologically relevant IgE-binding molecule on LC of AD 
patients. 
Although signal transduction via the FcERI on LC has yet 
to be demonstrated, it is attractive to speculate that antigeni- 
cally or artificially crosslinked IgE on LC may stimulate events 
in these cells  similar to those occurring in mast cells and 
basophils, e.g., biosynthesis and secretion of arachidonic acid 
metabolites (37) and cytokines (38, 39). The recent observa- 
tion by Mudde et al. (40) that IgE-bearing I.C are superior 
to IgE-negative LC in their capacity to present house dust 
antigens to sensitized T cells, and that this in vitro function 
correlates with the in vivo presence of a positive delayed patch 
reaction to house dust antigen, indicates that the FceRI on 
LC may also play a crucial role in the uptake and processing 
of allergens by these cells.  Should further studies establish 
or substantiate the role of this receptor in these processes, 
the FceRI on LC might be an ideal target for topical therapy 
of allergic skin diseases. 
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